#68
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians should understand that CBG (cannabigerol) topicals represent a distinct product category with different pharmacokinetics than systemic cannabinoids, yet clinical evidence for CBG efficacy remains limited compared to CBD, making it important to counsel patients on the lack of robust safety and efficacy data before recommending or endorsing these products. As CBG topicals gain market prominence, clinicians may encounter patients using these products for localized pain or inflammation and should be prepared to discuss the absence of standardized dosing, quality control variability in hemp-derived products, and potential drug interactions with topical or systemic medications. Understanding the distinction between marketing claims and clinical evidence will help clinicians provide informed guidance to patients
Cannabigerol (CBG), a minor cannabinoid increasingly isolated from hemp, is emerging as a commercial ingredient in topical products marketed for rapid pain and inflammation relief, often combined with CBD and other cannabinoids. While consumer demand for CBG topicals is growing rapidly, clinical evidence supporting CBG’s efficacy in humans remains limited compared to CBD, with most mechanistic data derived from in vitro and animal studies suggesting potential anti-inflammatory and analgesic properties. For clinicians counseling patients on topical cannabinoid products, CBG formulations represent an understudied category where marketing claims frequently outpace the published clinical evidence base. The proliferation of these products reflects broader market trends toward cannabinoid diversification and patient interest in alternatives to conventional topical analgesics, though standardization, quality control, and rigorous human trials remain gaps in the evidence landscape. Clinicians should remain cautious about endorsing specific CBG topical brands while acknowledging that patients may experiment with these products and should educate themselves on product composition, third-party testing, and lack of proven superiority over established topical options. The practical takeaway is that while CBG topicals may eventually prove beneficial, clinicians should currently frame these products as experimental consumer goods rather than evidence-based therapeutic options and encourage patients to report outcomes if they choose to use them.
“What we’re seeing with CBG topicals is patients finally having a targeted option for localized inflammation without the systemic effects of oral cannabinoids, but we need rigorous pharmacokinetic studies before we can make specific claims about absorption rates or mechanism of action in human tissue.”
? The emerging market for CBG (cannabigerol) topical products reflects growing consumer interest in minor cannabinoids beyond CBD, though clinicians should recognize that robust efficacy data for CBG remains limited compared to the already modest evidence base for topical cannabinoids generally. While in vitro and animal studies suggest CBG may have anti-inflammatory properties, human clinical trials evaluating topical CBG formulations are sparse, and marketed products often combine multiple ingredients (cooling agents, other cannabinoids) that confound attribution of any observed effects. The rapid commercialization of these products outpaces the regulatory oversight and standardized testing that would allow clinicians to confidently advise patients on safety, potency, or consistency across brands. When patients ask about CBG topicals for pain or inflammation, providers should acknowledge the preliminary mechanistic rationale while being transparent that evidence for clinical benefit is not established, recommend products with third-party testing when used
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
